Routine vitamin supplementation provides normal serum vitamin A but not vitamin E concentrations in CF patients  by Stezowska, S. et al.
11. Nutrition S93
372 Routine vitamin supplementation provides normal serum
vitamin A but not vitamin E concentrations in CF patients
S. Stezowska1, S. Drzymala-Czyz2, A. Lisowska1, A. Popiel3, W. Cichy1,
J. Walkowiak1. 11st Chair of Pediatrics, University of Medical Sciences, Poznan,
Poland; 2Dept Human Nutrition & Hygiene, Agricultural University, Poznan,
Poland; 33rd Chair of Pediatrics, University of Medical Sciences, Poznan, Poland
Cystic ﬁbrosis is a complex disease and leads to the deﬁciency of fat soluble
vitamins. Therefore, patients routinely undergo supplementation.
The aim of the study was: (1) to assess serum concentrations of vitamin A and E,
(2) to analyze the relationship between clinical expression of the disease and body
resources of these vitamins.
Material and Methods: The study comprised 43 CF patients in whom serum
vitamin A and E concentrations were determined (HPLC). The nutritional status
was assessed on the basis of Z-scores for body height and weight. Exocrine
pancreatic secretion (fecal elastase-1, ELISA) and lung function (FEV1) served
as markers of CF clinical expression.
Results: The ranges of vitamin A and E concentrations (median; mean±SEM)
were as follow: 133–872 ng/mL (351; 377±26) and undetectable-15.6mg/mL (8.9;
8.5±0.7). In all but one CF patients vitamin A levels were normal. Undetectable
and abnormal serum vitamin E levels were found in 17 (39.5%) and 35 (81.4%)
patients, respectively. Signiﬁcantly lower vitamin E concentrations (p< 0.04) were
found in subjects with worse nutritional status. Similarly, vitamin E body resources
correlated to fecal elastase-1 (r = 0.406, p< 0.006).
Conclusions: Routine vitamin supplementation with available in Poland water-
soluble preparation provides normal serum vitamin A concentrations. However, it
is ineffective in case of vitamin E. It seems that clinical expression of the disease
plays some role for body resources of vitamin E and does not inﬂuence signiﬁcantly
vitamin A levels.
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Aims: to assess the vitamin D status of CF patients with different degree of
exocrine pancreatic insufﬁciency taking pancreatic enzymes supplements and to
compare it with vitamin D level in the reference group.
Methods: serum 25-hydroxyvitamin D (25OHD) level was examined in 24 patients
with CF aged 2−22 years, related to faecal elastase-1 (FE-1) values, disease severity,
serum calcium concentration and compared to the age- and gender-matched control
with chronic lung diseases.
Results: All CF patients had low levels of 25OHD (<40 ng/ml). 41.7% of the
patients were vitamin D insufﬁcient (<20 ng/ml), in 16.6% children severely low
vitamin D levels (<10 ng/ml) were seen. In 16.6% control subjects 25OHD level
was normal. In the 25OHD <20 ng/ml and <10 ng/ml groups were only 12.5% and
4.2% of the patients respectively. Mean values of 25OHD content during the dark
season (16.28±8.54; 22±13.1) were signiﬁcantly lower as compared with the bright
season (27.9±13.2; 34.52±9.4 respectively) in both groups. 25OHD levels were
decreased in CF patients during the whole year as compared with control subjects.
Vitamin D insufﬁciency was associated with the age growth. No relationship with
25OHD content and gender, CF severity, genotype was found. The serum levels of
calcium were lower than normal in 33.3% CF cases but there was no correlation with
25OHD concentration. The values of FE-1 were decreased in 83.3% CF patients,
in 16.7% cases pancreatic activity was normal. No correlation between pancreatic
function measured as FE-1 and 25OHD concentration, serum levels of calcium was
noted.
Conclusion: Despite the adequate supplementation of pancreatic enzymes and ab-
sence of clinical symptoms of malabsorption serum 25OHD concentration remains
low in children and adolescents with CF.
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CF patients may have deranged lipid metabolism. We wanted to determine the
pattern of fatty acids (FA) in serum phospholipids (PLs) of Scandinavian CF patients
and correlate the pattern to nutritional status and prognostic parameters as a basis
for further studies.
Patients: 710 CF patients (362 males), mean age 20.4 (median 18.0, range
0.3−65.9) yrs were investigated. 86% were pancreatic insufﬁcient.
Methods: The FA pattern in s-PLs of each patient was analyzed with capillary
gas chromatography. Linoleic (LA), arachidonic (AA), eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acid were correlated with the PUFA intake calculated from
a 7 day dietary food record (n = 343), and with different clinical parameters.
Results: Mean (mole%) was for LA 16.0, AA 7.5, EPA 1.0, DHA 2.6. In Norway
more patients showed higher levels of EPA and DHA compared to patients in
Denmark and Sweden. Females had a higher DHA level than males (2.7 vs 2.5,
p< 0.002). There were no other gender differences, nor any age differences. There
was a positive correlation between LA and FEV1.0 (all ages), p< 0.001 and a
negative correlation with HbA1C, p< 0.00001. There were no correlations between
n-3 fatty acids (EPA and DHA) and IgG but a negative one with LA.
Conclusion: Generally PUFA levels were low showing different patterns. Unexpect-
edly, LA but not EPA and DHA correlated with FEV1 and HbA1c. This warrants
further investigation.
Supported by: Swedish Heart Lung Foundation, Stiftelsen Frimurare-Barnhuset i
Stockholm, Norwegian and Swedish CF Association and an unrestricted grant by
Solvay Pharma.
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Aim: The study objective was to evaluate whether the earlier observed changes
in the fatty acid proﬁle as result of DHA supplementation, could be maintained
during longer study trials and to observe its effect on the clinical outcome of cystic
ﬁbrosis (CF) patients.
Method: A 1 year lasting double blind placebo controlled study was performed
in DF508 homozygous CF patients above the age of 6. Clinical data including
pulmonary function and number of infections were collected. Blood for the
determination of the fatty acid (FA) composition of serum pospholipid, vitamin E,
liver enzymes, immunoglobulins, erythrocyte sedimentation rate and coagulation
was drawn at the beginning and every 6 months after the start of the study.
Results: Seventeen patients were included, one dropped out. The treatment group
was supplemented with an algal DHA-rich oil and the control group with sunﬂower
seed oil. There was no difference between controls and treatment group for W/H%,
caloric intake, FEV1% and FVC% at the start of the study and after 1 year of
supplements. The phospholipid FA composition did not change in the control
group. The treatment group had a signiﬁcant increase in DHA and eicosapentaenoic
acid (EPA) concentration. A concomitant decrease of dihomo-gammalinolenic
acid, arachidonic acid, 22:5 n-6 and Mead acid was observed. The laboratory
results showed no changes in vitamin E level, liver enzymes, albumin, erythrocyte
sedimentation rate and IgG concentration in neither placebo nor intervention group.
Conclusion: Although DHA-rich oil shifted the serum phospholipid FAs to a less
pro-inﬂammatory proﬁle no conclusive clinical improvement could be observed
so far.
